New Weight-Loss drug ZT002 enters early human testing

NCT ID NCT06371326

Completed Disease control Sponsor: Beijing QL Biopharmaceutical Co.,Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial tested the safety and tolerability of ZT002, an injectable drug for weight loss, in 28 adults with overweight or obesity. Participants received multiple doses of ZT002 or a placebo to see how the body processes the drug and if any side effects occur. The study is complete, but results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ZT002 injection
What this could lead to: If safe and effective, ZT002 could become a new treatment option for weight management in people with overweight or obesity.
What could go wrong: This is a very early Phase 1 trial with only 28 participants, so it's too soon to know if ZT002 works or is safe long-term. Side effects are unknown at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT OR OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVERWEIGHT OR OBESITY

Contacts and locations

Locations

First Affiliated Hospital of Bengbu Medical College

Bengbu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.